The potential utility of various MUC1-based vaccine strategies has shown promise in eliciting immune responses in preclinical trials, leading to clinical trials in several cancers, including PDA, that have demonstrated a range of effects on humoral and T cell responses and patient survival (Gao et al., 2020). This evidence concerns the gene MUC1 and cancer.